Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

332 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Clinical relevance of exosome-derived microRNAs in Ovarian Cancer: Looking for new tumor biological fingerprints.
Fanale D, Corsini LR, Bono M, Randazzo U, Barraco N, Brando C, Cancelliere D, Contino S, Giurintano A, Magrin L, Pedone E, Perez A, Piraino P, Pivetti A, Giovanni ED, Russo TDB, Prestifilippo O, Gennusa V, Pantuso G, Russo A, Bazan V. Fanale D, et al. Among authors: bono m. Crit Rev Oncol Hematol. 2024 Jan;193:104220. doi: 10.1016/j.critrevonc.2023.104220. Epub 2023 Nov 29. Crit Rev Oncol Hematol. 2024. PMID: 38036154 Review.
Can the tumor-agnostic evaluation of MSI/MMR status be the common denominator for the immunotherapy treatment of patients with several solid tumors?
Fanale D, Corsini LR, Scalia R, Brando C, Cucinella A, Madonia G, Dimino A, Filorizzo C, Barraco N, Bono M, Fiorino A, Magrin L, Sciacchitano R, Perez A, Russo TDB, Pantuso G, Russo A, Bazan V. Fanale D, et al. Among authors: bono m. Crit Rev Oncol Hematol. 2022 Feb;170:103597. doi: 10.1016/j.critrevonc.2022.103597. Epub 2022 Jan 13. Crit Rev Oncol Hematol. 2022. PMID: 35033663 Review.
BRCA1/2 variants of unknown significance in hereditary breast and ovarian cancer (HBOC) syndrome: Looking for the hidden meaning.
Fanale D, Pivetti A, Cancelliere D, Spera A, Bono M, Fiorino A, Pedone E, Barraco N, Brando C, Perez A, Guarneri MF, Russo TDB, Vieni S, Guarneri G, Russo A, Bazan V. Fanale D, et al. Among authors: bono m. Crit Rev Oncol Hematol. 2022 Apr;172:103626. doi: 10.1016/j.critrevonc.2022.103626. Epub 2022 Feb 10. Crit Rev Oncol Hematol. 2022. PMID: 35150867 Review.
Programmed Death Ligand 1 (PD-L1) as a Predictive Biomarker for Pembrolizumab Therapy in Patients with Advanced Non-Small-Cell Lung Cancer (NSCLC).
Incorvaia L, Fanale D, Badalamenti G, Barraco N, Bono M, Corsini LR, Galvano A, Gristina V, Listì A, Vieni S, Gori S, Bazan V, Russo A. Incorvaia L, et al. Among authors: bono m. Adv Ther. 2019 Oct;36(10):2600-2617. doi: 10.1007/s12325-019-01057-7. Epub 2019 Aug 20. Adv Ther. 2019. PMID: 31432460 Free PMC article. Review.
BRCA1/2 pathogenic variants in triple-negative versus luminal-like breast cancers: genotype-phenotype correlation in a cohort of 531 patients.
Incorvaia L, Fanale D, Bono M, Calò V, Fiorino A, Brando C, Corsini LR, Cutaia S, Cancelliere D, Pivetti A, Filorizzo C, La Mantia M, Barraco N, Cusenza S, Badalamenti G, Russo A, Bazan V. Incorvaia L, et al. Among authors: bono m. Ther Adv Med Oncol. 2020 Dec 16;12:1758835920975326. doi: 10.1177/1758835920975326. eCollection 2020. Ther Adv Med Oncol. 2020. PMID: 33403015 Free PMC article.
Prevalence and Spectrum of Germline BRCA1 and BRCA2 Variants of Uncertain Significance in Breast/Ovarian Cancer: Mysterious Signals From the Genome.
Fanale D, Fiorino A, Incorvaia L, Dimino A, Filorizzo C, Bono M, Cancelliere D, Calò V, Brando C, Corsini LR, Sciacchitano R, Magrin L, Pivetti A, Pedone E, Madonia G, Cucinella A, Badalamenti G, Russo A, Bazan V. Fanale D, et al. Among authors: bono m. Front Oncol. 2021 Jun 11;11:682445. doi: 10.3389/fonc.2021.682445. eCollection 2021. Front Oncol. 2021. PMID: 34178674 Free PMC article.
Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors.
Dimino A, Brando C, Algeri L, Gristina V, Pedone E, Peri M, Perez A, De Luca I, Sciacchitano R, Magrin L, Bazan Russo TD, Bono M, Barraco N, Contino S, La Mantia M, Galvano A, Badalamenti G, Russo A, Bazan V, Incorvaia L. Dimino A, et al. Among authors: bono m. Cancers (Basel). 2022 Dec 29;15(1):216. doi: 10.3390/cancers15010216. Cancers (Basel). 2022. PMID: 36612211 Free PMC article. Review.
Theranostic biomarkers and PARP-inhibitors effectiveness in patients with non-BRCA associated homologous recombination deficient tumors: Still looking through a dirty glass window?
Incorvaia L, Perez A, Marchetti C, Brando C, Gristina V, Cancelliere D, Pivetti A, Contino S, Di Giovanni E, Barraco N, Bono M, Giurintano A, Bazan Russo TD, Gottardo A, Cutaia S, Pedone E, Peri M, Corsini LR, Fanale D, Galvano A, Scambia G, Badalamenti G, Russo A, Bazan V. Incorvaia L, et al. Among authors: bono m. Cancer Treat Rev. 2023 Dec;121:102650. doi: 10.1016/j.ctrv.2023.102650. Epub 2023 Oct 31. Cancer Treat Rev. 2023. PMID: 37939446 Free article. Review.
Hereditary Breast and Ovarian Cancer in Families from Southern Italy (Sicily)-Prevalence and Geographic Distribution of Pathogenic Variants in BRCA1/2 Genes.
Incorvaia L, Fanale D, Badalamenti G, Bono M, Calò V, Cancelliere D, Castiglia M, Fiorino A, Pivetti A, Barraco N, Cutaia S, Russo A, Bazan V. Incorvaia L, et al. Among authors: bono m. Cancers (Basel). 2020 May 5;12(5):1158. doi: 10.3390/cancers12051158. Cancers (Basel). 2020. PMID: 32380732 Free PMC article.
Detection of Germline Mutations in a Cohort of 139 Patients with Bilateral Breast Cancer by Multi-Gene Panel Testing: Impact of Pathogenic Variants in Other Genes beyond BRCA1/2.
Fanale D, Incorvaia L, Filorizzo C, Bono M, Fiorino A, Calò V, Brando C, Corsini LR, Barraco N, Badalamenti G, Russo A, Bazan V. Fanale D, et al. Among authors: bono m. Cancers (Basel). 2020 Aug 25;12(9):2415. doi: 10.3390/cancers12092415. Cancers (Basel). 2020. PMID: 32854451 Free PMC article.
332 results